Premium
Antiepileptic Drug Treatment of West Syndrome
Author(s) -
Ito Masatoshi
Publication year - 1998
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.1998.tb05148.x
Subject(s) - medicine , pediatrics , epilepsy , drug , pharmacotherapy , psychiatry
Summary: We sent questionnaires about current therapy for West syndrome (WS) to 208 institutions at which the pediatric members of the Japan Epilepsy Society were in residence. One hundred twenty‐nine institutions (62%) responded. Thirty‐eight institutions (29.5%) treated symptomatic and cryptogenic WS differently. Vitamin B 6 was the most preferred first‐line drug, followed by the combination of vitamin B 6 and valproate (VPA) or monotherapy with VPA. ACTH was the third choice among drugs. The combination therapy of vitamin B 6 and VPA was effective in 58.3% of the patients with symptomatic WS.